{"disease":{"id":"treatment-of-adult-patients-with-type-iv-hyperlipidemia-with-very-high-serum-triglyceride-elevations-2-000-mg-dl-presenting-risk-of-pancreatitis-unresponsive-to-diet","name":"Treatment of adult patients with Type IV hyperlipidemia with very high serum triglyceride elevations (>2,000 mg/dL) presenting risk of pancreatitis unresponsive to diet","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":1,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"lopid","indication_name":"Treatment of adult patients with Type IV hyperlipidemia with very high serum triglyceride elevations (>2,000 mg/dL) presenting risk of pancreatitis unresponsive to diet","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lopid","generic_name":"Gemfibrozil","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"PPAR-alpha (Peroxisome Proliferator-Activated Receptor Alpha)","drug_class":"Peroxisome Proliferator Receptor alpha Agonist [EPC]","quality_score":44,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[],"total":0},"guidelines":[{"drug_id":"lopid","guideline_body":"FDA label","recommendation":"Gemfibrozil is indicated as adjunctive therapy to diet for treatment of adult patients with very high elevations of serum triglyceride levels (Type IV hyperlipidemia) who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them.","line_of_therapy":"adj","evidence_grade":"B","guideline_year":null},{"drug_id":"lopid","guideline_body":"FDA label","recommendation":"Gemfibrozil is indicated as adjunctive therapy to diet for treatment of adult patients with very high elevations of serum triglyceride levels (Type V hyperlipidemia) who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them.","line_of_therapy":"adj","evidence_grade":"B","guideline_year":null},{"drug_id":"lopid","guideline_body":"FDA label","recommendation":"Gemfibrozil is indicated as adjunctive therapy to diet for reducing the risk of developing coronary heart disease in Type IIb patients without history or symptoms of existing coronary heart disease who have had an inadequate response to weight loss, dietary therapy, exercise, and other pharmacologic agents (such as bile acid sequestrants and nicotinic acid) and who have the following triad of lipid abnormalities: low HDL-cholesterol levels in addition to elevated LDL-cholesterol and elevated tri","line_of_therapy":"adj","evidence_grade":"B","guideline_year":null}],"source":"Drug Landscape verified database"}